



09-22-06

Jfw/Jmge


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: FRIESEN et al. Examiner: Unknown  
Serial No.: 10/584332 Group Art Unit: Unknown  
Filed: June 23, 2006 Docket: 12695.0037USWO  
Confirmation No.: 2032 Notice of Allow. N/A  
Date:  
Due Date: September 23, 2006  
Title: COMBINATION THERAPIES EMPLOYING A COMPOSITION COMPRISING A HMG COA REDUCTASE INHIBITOR AND A VITAMIN B6 RELATED COMPOUND

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 841294748 US  
Date of Deposit: September 21, 2006

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

By:   
Name: John Junkers

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**23552**  
PATENT TRADEMARK OFFICE


Sir:

We are transmitting herewith the attached:

- Transmittal Sheet in duplicate containing Certificate of Mailing
- Information Disclosure Statement, Form 1449, 17 Reference(s)
- Other: International Search Report, Form PCT/IB/326, Form PCT/IB/373, Form PCT/IB/237
- Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

Merchant & Gould P.C.  
P.O. Box 2903  
Minneapolis, MN 55402-0903  
612.332.5300

By:   
Name: Brian R. Dorn  
Reg. No.: 57,395  
BRD



S/N 10/584322

PATENT


AIPPE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	FRIESEN et al.	Examiner:	Unknown
Serial No.:	10/584322	Group Art Unit:	2032
Filed:	June 23, 2006	Docket No.:	12695.0037USWO
Title:	COMBINATION THERAPIES EMPLOYING A COMPOSITION COMPRISING A HMG COA REDUCTASE INHIBITOR AND A VITAMIN B6 RELATED COMPOUND		

CERTIFICATE UNDER 37 CFR 1.10:  
"Express Mail" mailing label number: EV 841294748 US  
Date of Deposit: September 21, 2006

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

By:   
Name: John Junkers

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. Enclosed for the Examiner's information is a copy of the International Search Report. At least some of the references were recently cited in an International Search Report mailed May 10, 2005.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application, which is not an application under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. § 1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

A concise explanation of the relevance of each non-English language document or other information is as follows (37 C.F.R. §1.98(a)(3)):

An English translation has been provided for German reference 24 61 742

An English abstract has been provided for WIPO reference 2004/006919 A1 which was published in Japanese.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.



Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Dated: As of September 21, 2016

  
\_\_\_\_\_  
Brian R. Dorn  
Reg. No. 57,395

BRD/ncb



## INFORMATION DISCLOSURE STATEMENT

## IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:  
12695.0037USWOApplication Number:  
10/584,332

Applicant: FRIESEN et al.

Filing Date: June 23, 2006

Group Art Unit: Unknown

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,288,716	02-1994	Speck			
	6,066,659	05-2000	Speck			
	2003/0049314 A1	03-2003	Liang et al.			
	6,576,256 B2	06-2003	Liang et al.			
	2003/0114424 A1	06-2003	Haque et al.			
	6,586,414 B2	07-2003	Haque et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	24 61 742	07-1976	Germany			Yes	
	97/38694	10-1997	WIPO				
	00/53606	09-2000	WIPO				
	00/57863	10-2000	WIPO				
	01/64692 A1	09-2001	WIPO				
	2004/006919 A1	01-2004	WIPO			Abstract	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Brattstrom et al. "Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate" Scandinavian Journal of Clinical Laboratory Investigation 50 (1990) p. 873-876
		Califf MD et al. "Myonecrosis After Revascularization Procedures" JACC Vol. 31 No. 2, ( February 1998) p. 241-251
		Chauhan, "Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease" Journal of Lipid Research Volume 44, (2003) p. 2019-2029
		Dumm et al. "Variations in the lipid profile of patients with chronic renal failure treated with pyridoxine" Lipids in Health and Disease (2003) 2(7) p. 1-6

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>		Docket Number: 12695.0037USWO	Application Number: 10/584,332
<b>IN AN APPLICATION</b>  (Use several sheets if necessary)		Applicant: FRIESEN et al.	
		Filing Date: June 23, 2006	Group Art Unit: Unknown

		The ESPRIT Investigators, "Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial" The Lancet Vol 356, (December 16, 2000) p. 2037-2044
		Frohlich M.D., "Lipoproteins and homocyst(e)ine as risk factors for atherosclerosis: Assessment and treatment" Canadian Journal of Cardiology vol 11, Supplement C (May 1995) p. 18C - 23C
		Hurt-Camejo et al. "Phospholipase A <sub>2</sub> in Vascular Disease" Circulation Research 89 (2001) p. 298-304
		Khayyal et al. "Effect of Magnesium Pyridoxal 5'-Phosphate Glutamate on Vascular Reactivity in Experimental Hypercholesterolemia" Drugs Exptl. Clin. Res XXIV(1) (1998) p. 29-40
		Krishnamurthi et al. "Effect of Pyridoxal 5'-Phosphate (PALP) on Human Platelet Aggregation, Dense Granule Release and Thromboxane B <sub>2</sub> Generation - Role of Schiff Base Formation" Thromb Haemostas (Stuttgart) 48 (2) (1982) p. 136-141
		Ray et al. "Lipid-lowering agents and the risk of hip fracture in a Medicaid Population" Injury Prevention 8 (2002) p. 276-279
		Wiklund et al. "Effects of simvastatin and atorvastatin on inflammation markers in plasma" Journal of Internal Medicine 251, (2002) p. 338-347

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.